云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

已收盘 04-27 16:08:30

35.380

-1.620

-4.38%

最高36.680	最低35.340	成交量242.10万
今开36.680	昨收37.000	日振幅3.62%
总市值125.25亿	流通市值125.25亿	总股本3.54亿
成交额8,636万	换手率0.68%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":35.38,"timestamp":1777277310002,"preClose":37,"halted":0,"volume":2421000,"delay":0,"changeRate":-0.04378378378378371,"floatShares":354000000,"shares":354000000,"eps":-1.022092372562543,"marketStatus":"已收盘","change":-1.62,"latestTime":"04-27 16:08:30","open":36.68,"high":36.68,"low":35.34,"amount":86358965,"amplitude":0.036216,"askPrice":35.4,"askSize":54000,"bidPrice":35.38,"bidSize":5500,"shortable":3,"etf":0,"ttmEps":-1.070325945200326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":5,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":37,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":0.885121,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952","defaultTab":"news","newsList":[{"id":"1129821057","title":"云顶新耀2025年业绩显著增长：收入跃升至17.07亿元 亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1129821057","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129821057?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:09","pubTimestamp":1776953388,"startTime":"0","endTime":"0","summary":"云顶新耀公布截至2025年12月31日止年度业绩，整体经营表现呈现快速增长与亏损收窄并行的态势。期内，公司实现收入17.07亿元人民币，同比2024年度的7.07亿元人民币上升141.5%。毛利率由2024年度的74.6%下降至69.3%，经剔除无形资产摊销后则由82.9%降至74.1%。在费用端，2025年度研发开支为5.11亿元人民币，较上年度的5.28亿元人民币有所减少。得益于收入放量及内部效率提升，年内亏损由2024年度的10.41亿元人民币降至2.98亿元人民币，亏损幅度明显缩窄。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀2025年业绩显著增长：收入跃升至17.07亿元 亏损大幅收窄","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629703216","title":"港股云顶新耀早盘涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629703216","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629703216?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:40","pubTimestamp":1776735647,"startTime":"0","endTime":"0","summary":"4月21日，云顶新耀(01952.HK)早盘涨超4%，截至发稿涨4.23%，报41.34港元，成交额2610.75万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604213711917794.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604213711917794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","01952","VXUS","BK4585","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629344703","title":"港股异动 | 云顶新耀(01952)早盘涨超4% 于2026年AACR年会首次公布EVM16人体临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629344703","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629344703?lang=zh_cn&edition=full","pubTime":"2026-04-21 09:35","pubTimestamp":1776735351,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀早盘涨超4%，截至发稿，涨4.23%，报41.34港元，成交额2610.75万港元。消息面上，据云顶新耀官微消息，近日，公司宣布在2026年美国癌症研究协会年会上公布其自主研发的mRNA个性化肿瘤治疗性疫苗EVM16单药治疗及联合PD-1抑制剂治疗晚期实体瘤的首次人体临床试验数据。结果显示，EVM16在晚期实体瘤患者中展现出良好的安全性和耐受性、显著的免疫原性及积极的初步疗效信号，支持进一步临床开发推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","VXUS","01952","BK1583","BK1161","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628229571","title":"【券商聚焦】交银国际维持云顶新耀(01952)买入评级 指其商业化能力持续验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2628229571","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628229571?lang=zh_cn&edition=full","pubTime":"2026-04-17 10:44","pubTimestamp":1776393869,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，2025年云顶新耀 收入同比+142%至17亿元，其中：1）耐赋康销售收入达14.43亿元，同比增超300%。2）依嘉销售收入2.62亿元，院内销售同比+44%，同时维适平已于2026年2月上市，预计两款产品今年将进行医保谈判、明年实现本地化供货。公司预计维适平销售峰值有望达50亿元。该机构认为，此次交易有望提升公司整体盈利，加速公司现有创新组合的医保覆盖和商业化进程。维持买入评级和84港元目标价。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979229","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167725355","title":"云顶新耀更新3月股份变动月报表，股本小幅上升","url":"https://stock-news.laohu8.com/highlight/detail?id=1167725355","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167725355?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:47","pubTimestamp":1775731664,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司于2026年4月9日披露2026年3月股份变动月报表。报告显示，截至2026年3月31日，公司注册股本维持在500,000,000股普通股，面值0.0001美元，总额为50,000美元，未发生增减变动。已发行股本方面，普通股于本月由353,581,158股增至353,584,408股，较上月底增加3,250股；库藏股份数量仍为零。上述增加主要来自本月行使期权发行新股3,250股，公司由此获得款项50,804港元。2026年3月底，公司仍维持各项激励计划正常有效，无回购或注销股份的情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626183691","title":"云顶新耀2.5亿美元收购海森新加坡：整合难度大、财务压力仍存，关联交易引发关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2626183691","media":"蓝鲸财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626183691?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:05","pubTimestamp":1775729131,"startTime":"0","endTime":"0","summary":"2025年海森新加坡公司营收5.66亿元。云顶新耀方面称。整合难度大、财务压力仍存，关联交易引发关注云顶新耀的想法的确很美好，但实际落地却依旧存在不小的挑战。根据公告，云顶新耀首期需支付1.5亿美元，还将承接海森生物约1.488亿美元的股东贷款，这些都将对去年归母净利润亏损2.98亿元的云顶新耀构成财务压力。云顶新耀收购海森新加坡公司，实际是康桥资本、合肥国资等资方借道云顶新耀，实现投资的部分退出。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775724890095579948","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["01952","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626197590","title":"140亿港元嘉兴药厂，17亿元买下新加坡资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2626197590","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626197590?lang=zh_cn&edition=full","pubTime":"2026-04-09 08:00","pubTimestamp":1775692811,"startTime":"0","endTime":"0","summary":"记者丨韩璐鄢子为嘉兴一家创新药企，海外落下一子。4月8日，云顶新耀董事会主席吴以芳宣布，拟收购一家新加坡企业，交易总价约为17亿元人民币。标的，为海森生物子公司。云顶新耀方面告诉《21CBR》记者，交易完成后，将取得海森新加坡在亚太的14款慢病成熟产品及商业化团队，同时可将国内产品拓展至亚太地区。2025年，云顶新耀收入为17亿元，增长一倍多。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604093698803544.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604093698803544.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","01952","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625962955","title":"云顶新耀(01952)与海森生物签署收购协议 亚太商业化版图扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2625962955","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625962955?lang=zh_cn&edition=full","pubTime":"2026-04-08 07:31","pubTimestamp":1775604672,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月8日，云顶新耀宣布，其新加坡全资附属公司EverSea Medicines  Pte. Ltd.与海森生物制药(亚洲)有限公司签署股权购买协议，拟收购后者全资附属公司海森生物制药(新加坡)有限公司全部股权。云顶新耀方面表示，通过本次收购，公司将把在中国市场已验证的商业化能力和创新药产品拓展至亚太地区，强化区域布局，加快现有及未来产品的市场准入与商业化进程，并为后续创新产品的国际化拓展奠定基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154808948","title":"云顶新耀董事长斥资3270万港元 于3月27日以每股38.12港元购入86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1154808948","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154808948?lang=zh_cn&edition=full","pubTime":"2026-03-30 12:18","pubTimestamp":1774844337,"startTime":"0","endTime":"0","summary":"3月27日，云顶新耀董事长在公开市场进行了一次大规模股份增持。根据披露信息，此次交易涉及86万股公司股份，总金额高达3270万港元，每股成交价格为38.12港元。这一举动彰显了公司高层对未来发展的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1583","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623398062","title":"云顶新耀(01952)获主要股东傅唯增持86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623398062","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623398062?lang=zh_cn&edition=full","pubTime":"2026-03-30 12:18","pubTimestamp":1774844307,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀(01952)发布公告，公司董事会获非执行董事、董事会荣誉主席兼公司主要股东傅唯先生告知，于2026年3月27日，傅唯先生透过其控制的公司于市场购入86万股公司普通股，总代价约为3270万港元，平均价格约为每股股份38.12港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"云顶新耀(01952)获主要股东傅唯增持86万股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623547361","title":"营收大涨142%，云顶新耀剑指2030年150亿元营收","url":"https://stock-news.laohu8.com/highlight/detail?id=2623547361","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623547361?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:30","pubTimestamp":1774830600,"startTime":"0","endTime":"0","summary":"2025年是“十四五”规划的收官之年，也是中国生物医药行业迈入高质量发展的关键分水岭。得益于多年积累并持续涌现的创新成果、不断加速的研发进展及深化的全球合作，一批具备核心竞争力的创新药企业脱颖而出，云顶新耀（01952.HK）便是其中的典型代表。日前，云顶新耀披露2025年业绩报告显示，全年实现总收入17.07亿元，同比大幅增长142%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603303688161385.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603303688161385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622758158","title":"云顶新耀2025年业绩亮眼 管理层详解双轮驱动战略与千亿市值目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2622758158","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622758158?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:49","pubTimestamp":1774622994,"startTime":"0","endTime":"0","summary":"3月26日，港股创新药企云顶新耀（1952.HK）举办2025年度业绩发布媒体沟通会，公司董事会主席吴以芳与首席执行官罗永庆携手亮相，详解全年业绩亮点与未来规划。数据显示，2025年公司实现总收入17.07亿元，同比大增142%；非国际财务准则下首次扭亏为盈，盈利1.87亿元，第四季度经营性现金流回正，现金储备达27.31亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273687502782.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1583","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622168918","title":"港股异动 | 云顶新耀(01952)早盘涨超8% 耐赋康销售驱动强劲增长 全年营收大增142%至17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622168918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622168918?lang=zh_cn&edition=full","pubTime":"2026-03-27 10:03","pubTimestamp":1774577020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀早盘涨超8%，截至发稿，涨8.36%，报37.58港元，成交额9885.59万港元。消息面上，云顶新耀发布年度业绩，公司全年营收同比大增142%至17.07亿元，非国际财务准则下首度实现扭亏为盈，录得利润1.87亿元，国际财务准则下亏损亦大幅收窄71%，经营性现金流成功转正。收益增加主要由于耐赋康在已商业化市场的销售额继续上升所致。云顶新耀表示，2026年将成为公司2030年战略的“执行之年”和实现转型的关键之年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155432498","title":"异动解读 | 云顶新耀盘中大涨5.13%，强劲财报及产品管线前景获市场认可","url":"https://stock-news.laohu8.com/highlight/detail?id=1155432498","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155432498?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:48","pubTimestamp":1774576105,"startTime":"0","endTime":"0","summary":"云顶新耀今日盘中股价大涨5.13%，市场表现活跃。消息面上，公司此前公布了2025年度财报并举行了媒体沟通会。财报显示，公司2025年全年总收入达17.07亿元，同比增长142%，并首次在非国际财务报告准则下实现扭亏为盈，净利润为1.87亿元。此外，公司新获批的精氨酸艾曲莫德片（维适平）被寄予厚望，预期峰值销售额可达50亿元。同时，公司计划让依拉环素和精氨酸艾曲莫德片参与国家医保谈判，以提升药品可及性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622818778","title":"云顶新耀：BD不会一卖了之，两款产品将参与医保谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2622818778","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622818778?lang=zh_cn&edition=full","pubTime":"2026-03-27 08:49","pubTimestamp":1774572540,"startTime":"0","endTime":"0","summary":"“对于BD，我们的态度是，不会‘卖青苗’，而是要找到战略上有协同、能力上能互补、财务上稳健的合作方，帮我们一起共同开发，而不是简单地把它卖掉，这是我们的原则。我们不是一卖了之，我们希望看到长远，能够帮助这些有突破性技术的产品，实现它的长远价值，这是我们最在乎的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686333750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686333750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1583","BK1161","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622198889","title":"云顶新耀(01952)2025年股东净亏损同比收窄71.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622198889","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622198889?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:04","pubTimestamp":1774487064,"startTime":"0","endTime":"0","summary":"金吾财讯 | 云顶新耀(01952)公告发布，截至2025年12月31日止，公司母公司拥有人应占净亏损为2.98亿元(人民币，下同)，同比减亏71.4%，每股基本净亏损0.89元，同比减亏72.5%。期内，录得收益17.07亿元，同比增长1.41倍；毛利润11.82亿元，同比增长1.24倍。期内，集团研发开支5.11亿元，分销及销售开支7.81亿元，一般行政开支2.77亿元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977287","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622883992","title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883992","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622883992?lang=zh_cn&edition=full","pubTime":"2026-03-26 07:23","pubTimestamp":1774481019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布截至2025年12月31日止年度业绩，集团收益人民币17.07亿元，同比增长141.51%;股东应占亏损2.98亿元;研发开支5.11亿元;毛利11.82亿元，同比增长124.32%。收益增加主要由于耐赋康在已商业化市场的销售额继续上升所致。在中国市场，将耐赋康纳入国家医保药品目录为关键的增长动力，以致截至2025年12月31日止年度的耐赋康收益大幅增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK1574","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166404916","title":"云顶新耀2025年度经营亏损收窄，股东应占亏损同比明显减少","url":"https://stock-news.laohu8.com/highlight/detail?id=1166404916","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166404916?lang=zh_cn&edition=full","pubTime":"2026-03-26 06:58","pubTimestamp":1774479538,"startTime":"0","endTime":"0","summary":"云顶新耀于2025年12月31日止年度录得经营亏损人民币千元613,955，除所得税前亏损人民币千元598,364；本集团权益持有人应占年内亏损为人民币千元297,766，较上一年度的人民币千元1,041,375有所减少。主要管理人员于报告期内的薪酬合计人民币千元130,672，其中包括薪金、津贴及实物利益人民币千元32,828，表现相隔红利人民币千元30,530，以股份为基础的付款开支人民币千元66,212，以及退休金计划供款人民币千元1,102。银行存款为人民币千元887,086，现金及现金等价物则为人民币千元1,779,828。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621005945","title":"港股云顶新耀-B午后涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621005945","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621005945?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:05","pubTimestamp":1774335944,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月24日，云顶新耀-B(01952.HK)午后涨近7%，截至发稿涨6.7%，报34.72港元，成交额7485.13万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682500195.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682500195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK4588","VXUS","BK1574","BK4585","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621566310","title":"港股异动 | 云顶新耀-B(01952)午后涨近7% 公司获得PSVT新药艾曲帕米鼻喷雾剂大中华权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2621566310","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621566310?lang=zh_cn&edition=full","pubTime":"2026-03-24 14:46","pubTimestamp":1774334780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，云顶新耀-B午后涨近7%，截至发稿，涨6.7%，报34.72港元，成交额7485.13万港元。消息面上，云顶新耀宣布，与箕星药业达成资产收购协议，获得艾曲帕米鼻喷雾剂在大中华区的开发、商业化及产品地产化权益。根据协议，云顶新耀将向箕星药业支付3000万美元首付款，及支付最高不超过2000万美元的开发里程碑付款。在中国，该产品用于治疗PSVT的新药上市申请已于2025年1月获中国国家药品监督管理局正式受理，预计将于2026年第三季度获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417934.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","BK1574","01952","BK1161","BK1583","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.0647},{"period":"1month","weight":0.0165},{"period":"3month","weight":-0.1186},{"period":"6month","weight":-0.2452},{"period":"1year","weight":-0.2026},{"period":"ytd","weight":0.0005}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.081606},{"month":5,"riseRate":0.4,"avgChangeRate":-0.02945},{"month":6,"riseRate":0.8,"avgChangeRate":0.307082},{"month":7,"riseRate":0.2,"avgChangeRate":-0.114966},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}